You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

The rapid evolution of cellular therapies for the treatment of hip osteonecrosis

Homma, Yasuhiroa,b; Sand, Theodorec; Hernigou, Philippeb

Current Orthopaedic Practice:
doi: 10.1097/BCO.0000000000000073
Review Articles
Abstract

Hip osteonecrosis is a pathological condition resulting from cellular impairment from reductions in osteoblast activity and the local mesenchymal stem cell population. Cell-based therapies could correct such deficiencies by providing stem and other progenitor cells potentially to improve the local cellular environment in the affected hip. A rationale for the use of cytotherapy as well as a description of the technique of autologous bone marrow concentrate implantation are provided in the context of treating hip osteonecrosis. Current problems and future challenges with cytotherapy and associated techniques are discussed.

Author Information

aDepartment of Orthopaedic Surgery, Juntindo University, Tokyo, Japan

bUniversity Paris East (UPEC), Hôpital Henri Mondor, 94010 Creteil, France

cCelling Biosciences, Austin, Texas

Financial Disclosure: The authors report no financial conflicts of interest.

Correspondence to Philippe Hernigou, MD, Department of Orthopaedic Surgery, University Paris East (UPEC), Hôpital Henri Mondor, 94010, Creteil, France Tel: +33149812601; fax: +33149812608; e-mail: philippe.hernigou@wanadoo.fr

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins